Scholars Central

Conference abstractPublished 8 Nov 2017

Predicting, avoiding and mitigating risk of failure when developing biotherapeutics

Authors: Yvette Stallwood

Lonza Biologics, UK

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

This presentation will discuss how in silico and in vitro methodologies are employed to perform a developability and immunogenicity risk assessment in order to highlight potential risks of failure for the development of biotherapeutics. In silico methods can be used to evaluate protein sequence and structure to assess the likelihood of immunogenic responses and potential manufacturability issues including aggregation and PTMs. Ex vivo T and B-Cell responses enable the assessment of overall immunogenicity risks; different approaches are highlighted to further identify processed and presented epitopes.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Proteomics & Bioinformatics.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Proteomics & Bioinformatics
  • SubjectBiochemistry & Biotechnology
  • BylineArticles whose byline prints “Yvette Stallwood”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels